163 related articles for article (PubMed ID: 26922659)
1. Antagonist Models for Relapse Prevention and Reducing HIV Risk.
Woody GE; Krupitsky E; Zvartau E
J Neuroimmune Pharmacol; 2016 Sep; 11(3):401-7. PubMed ID: 26922659
[TBL] [Abstract][Full Text] [Related]
2. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available.
Krupitsky E; Zvartau E; Woody G
Curr Psychiatry Rep; 2010 Oct; 12(5):448-53. PubMed ID: 20640538
[TBL] [Abstract][Full Text] [Related]
3. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
Lee JD; Friedmann PD; Boney TY; Hoskinson RA; McDonald R; Gordon M; Fishman M; Chen DT; Bonnie RJ; Kinlock TW; Nunes EV; Cornish JW; O'Brien CP
Contemp Clin Trials; 2015 Mar; 41():110-7. PubMed ID: 25602580
[TBL] [Abstract][Full Text] [Related]
4. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
[TBL] [Abstract][Full Text] [Related]
5. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
Bisaga A; Sullivan MA; Cheng WY; Carpenter KM; Mariani JJ; Levin FR; Raby WN; Nunes EV
Drug Alcohol Depend; 2011 Dec; 119(1-2):e23-9. PubMed ID: 21715107
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone for heroin dependence treatment in St. Petersburg, Russia.
Krupitsky EM; Zvartau EE; Masalov DV; Tsoi MV; Burakov AM; Egorova VY; Didenko TY; Romanova TN; Ivanova EB; Bespalov AY; Verbitskaya EV; Neznanov NG; Grinenko AY; O'Brien CP; Woody GE
J Subst Abuse Treat; 2004 Jun; 26(4):285-94. PubMed ID: 15182893
[TBL] [Abstract][Full Text] [Related]
7. Naltrexone: Not Just for Opioids Anymore.
Sudakin D
J Med Toxicol; 2016 Mar; 12(1):71-5. PubMed ID: 26546222
[TBL] [Abstract][Full Text] [Related]
8. [The use of different forms of naltrexone in the treatment of opioid dependence].
Krupitskiĭ EM; Zvartau EE; Blokhina EA; Woody G
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(11 Pt 2):66-72. PubMed ID: 22611701
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic treatments for drug addiction: alcohol and opiates.
Haile CN; Kosten TA; Kosten TR
Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566
[TBL] [Abstract][Full Text] [Related]
10. [Limited role of naltrexone in the treatment of opiate addiction].
van Brussel GH
Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
[TBL] [Abstract][Full Text] [Related]
11. [An interim analysis of the results of treatment program implementation with the use of injectable extended-release naltrexone for opioid addicted patients].
Agibalova TV; Nedobylskiy OV; Poplevchenkov KN; Sirotko II; Shcherban AV; Tsarev SA
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):32-34. PubMed ID: 28745668
[TBL] [Abstract][Full Text] [Related]
12. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
13. Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.
Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Tsoy M; Wahlgren V; Burakov A; Masalov D; Romanova TN; Palatkin V; Tyurina A; Yaroslavtseva T; Sinha R; Kosten TR
Drug Alcohol Depend; 2013 Oct; 132(3):674-80. PubMed ID: 23683793
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence].
Kato H
Nihon Arukoru Yakubutsu Igakkai Zasshi; 2008 Oct; 43(5):697-704. PubMed ID: 19068776
[TBL] [Abstract][Full Text] [Related]
15. The Utilization of Low Dose Naltrexone for Chronic Pain.
Poliwoda S; Noss B; Truong GTD; Creech ZA; Koushik SS; Urits I; Viswanath O
CNS Drugs; 2023 Aug; 37(8):663-670. PubMed ID: 37505425
[TBL] [Abstract][Full Text] [Related]
16. Opioid Use Disorders.
Sharma B; Bruner A; Barnett G; Fishman M
Child Adolesc Psychiatr Clin N Am; 2016 Jul; 25(3):473-87. PubMed ID: 27338968
[TBL] [Abstract][Full Text] [Related]
17. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
[TBL] [Abstract][Full Text] [Related]
18. Psychiatric symptoms, quality of life, and HIV status among people using opioids in Saint Petersburg, Russia.
Desrosiers A; Blokhina E; Krupitsky E; Zvartau E; Schottenfeld R; Chawarski M
Drug Alcohol Depend; 2017 Mar; 172():60-65. PubMed ID: 28130990
[TBL] [Abstract][Full Text] [Related]
19. Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research.
Jones HE; Chisolm MS; Jansson LM; Terplan M
Addiction; 2013 Feb; 108(2):233-47. PubMed ID: 22471668
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.
Mannelli P; Patkar AA; Peindl K; Murray HW; Wu LT; Hubbard R
J Clin Psychopharmacol; 2007 Oct; 27(5):468-74. PubMed ID: 17873678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
